Payer decisions drive revenue through impact on price and volumes. In order to be commercially successful, the price and clinical evidence need to be planned early on. Also, investors and shareholders value certainty on pricing and funding situations beyond commercial availability. Within the Invest in Ottawa & P&N breakfast seminar, attendees will learn and get insights from the reimbursement veteran Dr. Stefan Walzer:
- Example of impact on share price
- How to prepare successfully?
- Understanding payer views and evaluations – are payers all the same?
- Top-level systems in US and Europe (EU-5)
- How are clinical data being assessed by payers? How can this be optimized early on?